As part of our ongoing mission to support the development of treatments for the five primary subtypes of congenital muscular dystrophy, Cure CMD has committed $375k in research grant funding for 2026-2028

Cure CMD is proud to partner with the Muscular Dystrophy Association and Cure ADSSL1 to support groundbreaking research at the Beggs Laboratory at Boston Children’s Hospital. This collaborative project will use next-generation genomic tools and AAV-based gene therapies to better understand disease mechanisms and advance potential treatments for SELENON-Related Myopathy, demonstrating how partnership across the rare disease community can accelerate progress toward meaningful t